JP2025504955A - 活性化可能な二重特異的抗ｃｄ４７および抗ｐｄ－ｌ１タンパク質ならびにその使用 - Google Patents

活性化可能な二重特異的抗ｃｄ４７および抗ｐｄ－ｌ１タンパク質ならびにその使用 Download PDF

Info

Publication number
JP2025504955A
JP2025504955A JP2024544969A JP2024544969A JP2025504955A JP 2025504955 A JP2025504955 A JP 2025504955A JP 2024544969 A JP2024544969 A JP 2024544969A JP 2024544969 A JP2024544969 A JP 2024544969A JP 2025504955 A JP2025504955 A JP 2025504955A
Authority
JP
Japan
Prior art keywords
cancer
seq
amino acid
protein
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504955A5 (https=
Inventor
ウィリアム ジェイムズ ジョナサン フィンレー，
Original Assignee
センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センテッサ ファーマシューティカルズ （ユーケー） リミテッド filed Critical センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Publication of JP2025504955A publication Critical patent/JP2025504955A/ja
Publication of JP2025504955A5 publication Critical patent/JP2025504955A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024544969A 2022-01-31 2023-01-31 活性化可能な二重特異的抗ｃｄ４７および抗ｐｄ－ｌ１タンパク質ならびにその使用 Pending JP2025504955A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263305003P 2022-01-31 2022-01-31
US63/305,003 2022-01-31
US202263309759P 2022-02-14 2022-02-14
US63/309,759 2022-02-14
US202263342283P 2022-05-16 2022-05-16
US63/342,283 2022-05-16
US202263348842P 2022-06-03 2022-06-03
US63/348,842 2022-06-03
PCT/EP2023/052366 WO2023144423A1 (en) 2022-01-31 2023-01-31 Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof

Publications (2)

Publication Number Publication Date
JP2025504955A true JP2025504955A (ja) 2025-02-19
JP2025504955A5 JP2025504955A5 (https=) 2026-02-06

Family

ID=85199086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544969A Pending JP2025504955A (ja) 2022-01-31 2023-01-31 活性化可能な二重特異的抗ｃｄ４７および抗ｐｄ－ｌ１タンパク質ならびにその使用

Country Status (9)

Country Link
US (1) US20250002585A1 (https=)
EP (1) EP4473012A1 (https=)
JP (1) JP2025504955A (https=)
KR (1) KR20240137084A (https=)
AU (1) AU2023210844A1 (https=)
CA (1) CA3251615A1 (https=)
IL (1) IL314395A (https=)
MX (1) MX2024009251A (https=)
WO (1) WO2023144423A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
CN111212852A (zh) 2017-08-18 2020-05-29 超人肆有限公司 结合剂
US20240124889A1 (en) * 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
CN116390939A (zh) * 2020-08-04 2023-07-04 埃克塞里艾克西斯公司 多重特异性结合剂及其用途

Also Published As

Publication number Publication date
IL314395A (en) 2024-09-01
US20250002585A1 (en) 2025-01-02
MX2024009251A (es) 2024-08-06
AU2023210844A1 (en) 2024-08-01
CA3251615A1 (en) 2023-08-03
EP4473012A1 (en) 2024-12-11
WO2023144423A1 (en) 2023-08-03
KR20240137084A (ko) 2024-09-19

Similar Documents

Publication Publication Date Title
TWI883057B (zh) 抗pd-l1抗體及抗體藥物結合物
JP2023109898A (ja) 治療抗体およびその使用
JP2021521181A (ja) 抗体−薬物コンジュゲートおよびがんの処置のためのそれらの使用
JP2024513921A (ja) 抗ｃｄ１２２抗体及びその使用
US20230203153A1 (en) Antibodies specific to abcb5 and uses thereof
KR20220110231A (ko) 항-αvβ6 항체 및 항체-약물 접합체
RS66837B1 (sr) Agensi sa dvostrukim vezivanjem za pd1 i vegfr2
JP2025526418A (ja) 二重特異性抗ｃ－Ｋｉｔ及び抗ＣＤ２０３Ｃ抗原結合分子ならびにそれらの使用
KR20220088428A (ko) 글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
US20250109206A1 (en) Activatable bispecific anti-cd3 and anti-pd-l1 proteins and uses thereof
JP2024543236A (ja) 抗ｖｉｓｔａ抗体及びその使用
US20250002585A1 (en) Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof
CN118786144A (zh) 可活化双特异性抗cd47和抗pd-l1蛋白质及其用途
WO2024218512A1 (en) Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof
EP4698562A1 (en) Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof
EA052759B1 (ru) Антитела против pd-l1 и конъюгаты антитело-лекарственное средство

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260129